BioLineRx (BLRX) Stock Soars on Liver Drug Licensing Agreement

NEW YORK (TheStreet) -- Shares of BioLineRx  (BLRX)  were surging 26.73% to $1.28 on heavy trading volume late afternoon Friday as the Israeli drug developer signed a liver treatment licensing agreement with BGN Technologies and Hadasit

BGN Technologies is the technology transfer and commercialization company of Ben-Gurion University, a public research university in Israel, the company said in a statement. 

Hadasit is the technology transfer company of the Hadassah Medical Organization, a hospital in Israel. 

The license allows for the development of a novel treatment, called BL-1220, for various liver failure conditions including end-stage liver disease and non-alcoholic steatohepatitis (NASH). 

The agreement was signed as part of BioLineRx's strategic partnership with Swiss pharmaceutical company Novartis (NVS). 

More than 7.95 million of the company's shares have changed hands so far today vs. its average volume of 323,826 shares per day.

BLRX Chart BLRX data by YCharts

More from Markets

Record Bull Market Poised to Run Further as Trump Frets Over Fed

Record Bull Market Poised to Run Further as Trump Frets Over Fed

Famed Chartist Marc Chaikin Gives Jim Cramer His Top Picks Wednesday Aug. 22

Famed Chartist Marc Chaikin Gives Jim Cramer His Top Picks Wednesday Aug. 22

Kardashian-Endorsed Ouai Likely Merger Fodder; Uber's C-Suite Takes Form - ICYMI

Kardashian-Endorsed Ouai Likely Merger Fodder; Uber's C-Suite Takes Form - ICYMI

Cohen Pleads Guilty, Manafort Found Guilty -- Any Market Impact?

Cohen Pleads Guilty, Manafort Found Guilty -- Any Market Impact?

Azealia Banks Confirms Elon Musk Smokes Weed

Azealia Banks Confirms Elon Musk Smokes Weed